Near-infrared AIE-active phosphorescent iridium(iii) complex for mitochondria-targeted photodynamic therapy

Abstract

Mitochondria-targeted photodynamic therapy (PDT) has recently been recognized as a promising strategy for effective cancer treatment. In this work, a mitochondria-targeted near-infrared (NIR) aggregation-induced emission (AIE)-active phosphorescent Ir(III) complex (Ir1)...

Towards Ruthenium(II)‐Rhenium(I) Binuclear Complexes as Photosensitizers for Photodynamic Therapy

“…Regarding the design of complex 5, we decided to use 4,7diphenyl-1,10-phenanthroline (Bphen) as an auxiliary ligand for the ruthenium in order to allow accessing a better light absorption (i. e., absorption at higher wavelength and with higher efficiency), as previously shown by our group. [27][28][29][30][31][32] Interestingly, the total charge of the binuclear complex could be easily modulated depending on the Re(I) chelator nature, which allows tuning the solubility of the whole complex. For the Re(I)CO 3 chelating part, we turned our attention towards dipicolylamine (DPA).…”

“…The synthesis of the Ru(II) complex 3 and the Ru(II)‐Re(I) complex 5 investigated in this work is detailed in Scheme 1. Regarding the design of complex 5 , we decided to use 4,7‐diphenyl‐1,10‐phenanthroline (Bphen) as an auxiliary ligand for the ruthenium in order to allow accessing a better light absorption (i. e., absorption at higher wavelength and with higher efficiency), as previously shown by our group [27–32] . Interestingly, the total charge of the binuclear complex could be easily modulated depending on the Re(I) chelator nature, which allows tuning the solubility of the whole complex.…”

Multifunctional Self-Assembled Nanoplatform with AIEgen and Rapamycin-Mediated Tumor Microenvironment Remodeling via mTOR Axis to Enhance Photodynamic Therapy

“…17−20 Additionally, it is well-known that PS triggers two main PDT mechanisms to produce various ROS: the type I mechanism that produces free radicals via electron transfer and the type II mechanism that produces singlet oxygen via energy transfer. 21 Currently, most of the developed PS are type II, which essentially rely on O 2 to produce ROS, so the ubiquitous hypoxic microenvironment of solid tumors limits the application. 22,23 Compared with type II PS, type I PS has less dependence on O 2 and more potent cytotoxicity of free radical ROS.…”

“…Since Academician Tang Benzhong introduced the new physical phenomenon of AIE in 2001, the development of AIEgens as a new generation of PS has received extensive attention. ,, AIEgens not only endow PS with strong fluorescence characteristics, making it easier to track but also increase the production rate of ROS of PS and play a more potent anticancer effect. − Additionally, it is well-known that PS triggers two main PDT mechanisms to produce various ROS: the type I mechanism that produces free radicals via electron transfer and the type II mechanism that produces singlet oxygen via energy transfer . Currently, most of the developed PS are type II, which essentially rely on O 2 to produce ROS, so the ubiquitous hypoxic microenvironment of solid tumors limits the application. , Compared with type II PS, type I PS has less dependence on O 2 and more potent cytotoxicity of free radical ROS. , Therefore, exploring type I AIEgens with high-performance ROS production is necessary to enhance the PDT efficacy.…”

Aggregation-Induced Near-Infrared Emission and Electrochemiluminescence of an Iridium(III) Complex for Ampicillin Sodium Sensing

“…In all, most studies on AIE metal iridium­(III) complexes are based on bidentate ligands such as ĈN and N̂N, and substituents such as long chains or hydroxyl and amino that are easy to form hydrogen bonds , in the ligands. Recently, iridium­(III) complexes with AIE properties have been applied in fingerprint visualization, , biological imaging, , organic diodes, , chemical sensors, , and other fields. − …”